Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.40 |
| ▸ | IKBKB | O14920 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | AGPAT2 | O15120 | 3/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13413991 | 0.92 | IKBKB (0.43) | IKBKBTP53MAPTHPGDALOX15 | |
| SCHEMBL3140989 | 0.86 | AGPAT2 (0.45) | TP53MAPTHPGDALOX15TSHR | |
| SCHEMBL3146198 | 0.86 | KMT2A (0.41) | KDRP2RX3TP53MAPTHPGD | |
| SCHEMBL3142025 | 0.85 | ADORA2A (0.41) | KDRP2RX3TP53MAPTHPGD | |
| SCHEMBL3141970 | 0.85 | AGPAT2 (0.45) | IKBKBTP53MAPTHPGDALOX15 | |
| SCHEMBL3232538 | 0.84 | P2RX3 (0.39) | KDRP2RX3TP53MAPTHPGD | |
| SCHEMBL13413990 | 0.83 | MAPT (0.41) | IKBKBTP53MAPTHPGDALOX15 | |
| SCHEMBL3239827 | 0.83 | KDM4E (0.43) | IKBKBTP53MAPTHPGDALOX15 | |
| SCHEMBL13448683 | 0.83 | ABL1 (0.39) | KDRP2RX3TP53MAPTHPGD | |
| SCHEMBL13414012 | 0.82 | RAB9A (0.49) | IKBKBTP53MAPTHPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-7582645-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | TYMP, DPYD, CCNA2 | KDR 1618/4885P2RX3 1430/4885IKBKB 690/4885 |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | CCNA2, MALT1, TPD52L2 | KDR 3725/4885P2RX3 1510/4885IKBKB 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.